PART II - RULES 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate) x
(a) The
reason described in reasonable detail in Part III of this form could not be
eliminated without unreasonable effort or expense;
(b) The
subject annual report, semi-annual report, transition report on Form 10-K, Form
20-F, Form 11-K, Form N-SAR or Form N-CSR or portion thereof, will be filed on
or before the fifteenth calendar day following the prescribed due date; or the
subject quarterly report or transition report on Form 10-Q, or portion thereof,
will be filed on or before the fifth calendar day following the prescribed due
date; and
(c) The
accountant's statement or other exhibit required by Rule 12b-25(c) has been
attached if applicable.
PART III - NARRATIVE
State below
in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or
the transition report or portion thereof, could not be filed within the
prescribed time period.
Bioanalytical
Systems, Inc. (the "Company") is unable to file its Form 10-K for the fiscal
year ended September 30, 2008, within the prescribed time period without
unreasonable effort and expense. Specifically, the Company requires
additional time to complete the work necessary to finalize its financial
statement disclosures related to its income taxes, including the review of such
disclosures by the Company's officers and directors, the Audit Committee of the
Board of Directors, and the Company's independent
auditor. Nevertheless, the Company anticipates completing such filing
on or before the fifteenth calendar day following the prescribed due
date.
PART
IV - OTHER INFORMATION
(1) Name
and telephone number of person to contact in regard to this
notification
Michael
R. Cox
|
(765)
|
463-4527
|
Name
|
(Area
Code)
|
(Telephone
Number)
|
(2) Have
all other periodic reports required under Section 13 or 15(d) of the Securities
Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during
the preceding 12 months or for such shorter period that the registrant was
required to file such report(s) been filed? If answer is no, identify
report(s).
x Yes o No
(3) Is
it anticipated that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by the earnings
statements to be included in the subject report or portion thereof?
o Yes x No
If so, attach
an explanation of the anticipated change, both narratively and quantitatively,
and, if appropriate, state the reasons why a reasonable estimate of the results
cannot be made:
BIOANALYTICAL
SYSTEMS, INC.
(Name
of Registrant as Specified in Charter)
has caused
this notification to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
Date:
December 30,
2008
|
By:
|
/s/ Michael
R. Cox |
|
|
|
Michael
R. Cox |
|
|
|
Vice
President, Finance and Administration, Chief
Financial Officer and Treasurer |
|
|
|
|
|
INSTRUCTION: The
form may be signed by an executive officer of the registrant or by any other
duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If
the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the
representative's authority to sign on behalf of the registrant shall be filed
with the form.
ATTENTION
Intentional
misstatements or omissions of fact constitute Federal Criminal Violations (See
18 U.S.C. 1001).